Drugs / [18F]-altanserin
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT05942716 | Sep 2024 → Sep 2027 expected | Tourette syndrome | Hospices Civils de Lyon | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03970239 | May 2019 → Feb 2022 | Parkinson disease, impulse control disorder | Hospices Civils de Lyon | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]-altanserin | “A highly selective 5-HT2A receptor ligand (\[18F\]-altanserin) will be injected to patients before each PET scan.” NCT05942716 ↗ |
| Known as | [18 Fluorine]-altanserin | “Positron Emission Tomography using [11 Carbon]-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile ([11C]-DASB) and [18 Fluorine]-altanserin ([18F]-altanserin)” NCT03970239 ↗ |
| Modality | Diagnostic / imaging agent | “[18F]-altanserin is a highly specific PET radiotracer” NCT03970239 ↗ |
| Route | Intravenous | “single intravenous administration of approximately 3.7 MBq/kg of [18F]-altanserin” NCT03970239 ↗ |